| Document |
Document Title |
|
WO/2023/181830A1 |
Provided is a cell preparation that has effective therapeutic effect on ischemic diseases. The cell preparation contains CD18-positive cells. This cell preparation is produced by: acquiring a buffy coat layer from a sample containing hem...
|
|
WO/2023/182192A1 |
The objective of the present invention is to provide a composition which is for inhibiting Pseudomonas syringae, contains alcohol, and can inhibit the growth of Pseudomonas syringae while inhibiting the production of IL-1α caused by the...
|
|
WO/2023/182460A1 |
The purpose of the present invention is to provide a novel detection method for chronic active Epstein-Barr virus (CAEBV) and a novel therapeutic pharmaceutical composition for CAEBV. The present invention provides a detection method for...
|
|
WO/2023/180245A1 |
According to the WHO, the population aged 60 and over will have doubled by 2050. Unfortunately, aging comes along with an explosion of aging-associated disorders, such as metabolic and cardiovascular diseases, bone and muscle weakening, ...
|
|
WO/2023/182185A1 |
The purpose of the present invention is to provide a novel compound having an affinity and/or inhibitory function specific to gingipains. The present invention provides a peptide, or a derivative thereof, or a salt of the peptide or deri...
|
|
WO/2023/182530A1 |
Obtained is an excellent anti-CD39 antibody. Provided is an antibody or an antigen-binding fragment that binds to CD39, and contains heavy-chain CDRs 1-3 and light-chain CDRs 1-3 containing a specific amino acid sequence. This antibody m...
|
|
WO/2023/182420A1 |
The purpose of the present invention is to provide a novel drug having excellent anti-malignant tumor effect. A drug characterized by comprising the combination of liposomes encapsulating an anti-malignant tumor agent with a bacterium.
|
|
WO/2023/180471A1 |
Inventors observe that the NButGT treatment increases the O-GlcNAcylation levels of cardiac proteins (p<0.05). Mean arterial pressure decreases 5 hours after ECC procedure compared to the sham group (sham: 95.7 ± 3.7; ECC: 69.8 ± 7.7; ...
|
|
WO/2023/182529A1 |
[Problem] To provide a pharmaceutical composition that is effective against diseases caused by immune abnormalities and the like. [Solution] This pharmaceutical composition contains chondroitin sulfate, an unsaturated fatty acid, vitamin...
|
|
WO/2023/179499A1 |
The present invention relates to the field of gene drug delivery, and particularly to a lipid compound having a glycerol skeleton, a lipid carrier based on the lipid compound, a nucleic acid lipid nanoparticle composition, and a pharmace...
|
|
WO/2023/180572A1 |
The invention relates to a method to obtain a preparation of nano plasma membrane vesicles (nPMVs), comprising the steps: providing eukaryotic cells; exposing the eukaryotic cells to conditions leading to vesiculation of the eukaryotic c...
|
|
WO/2023/179366A1 |
An oxadiazole derivative, a preparation method therefor and the use thereof. The oxadiazole derivative has a structure as shown in formula I. The oxadiazole derivative has a very good agonistic effect on S1P1, and can be used for treatin...
|
|
WO/2023/182298A1 |
The present invention provides a therapeutic or prophylactic medicine for fragile X syndrome containing a compound represented by formula (I) (see the attached description for the symbols in formula (I)) or formula (II) (see the attached...
|
|
WO/2023/181755A1 |
Provided is: a highly-safe and low-cost expression regulator for a factor particularly involved in maturation, moisture retention, or barrier function of the skin; an expression enhancer for an antimicrobial peptide; an expression enhanc...
|
|
WO/2023/182475A1 |
The present invention addresses the problem of developing a method that can more conveniently remove senescent cells within an organism while having few side effects. The present inventors focused on the mechanism by which ammonia, whi...
|
|
WO/2023/182572A1 |
The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a pharmaceutical compos...
|
|
WO/2023/182243A1 |
The gene expression regulator is a microparticle that contains miRNA for which the target gene is a gene related to the expression of at least one protein from amyloid precursor protein (APP), β-secretase (BACE1), NMDA-activating protei...
|
|
WO/2023/179392A1 |
Provided are a B7H3 antibody and a bifunctional antibody comprising same. The monoclonal antibody 8H9 of B7H3 is humanized, and the humanized antibody can effectively block the immunosuppressive effect caused by B7H3. In addition, a fusi...
|
|
WO/2023/176554A1 |
The present invention provides a pharmaceutical composition used to treat or prevent a diseases or disorder caused by activation of Ca2+/calmodulin-dependent kinase II, the pharmaceutical composition containing a compound represented by ...
|
|
WO/2023/176849A1 |
Provided is a glucuronidase activator containing, as an active ingredient, Levilactobacillus brevis (Levilactobacillus brevis) strain I-3141 (accession number: CECT 7480).
|
|
WO/2023/176871A1 |
The present description discloses a means that enables the prevention of the decrease in the amount of reduced coenzyme Q10 due to oxidization during the storage of a solid composition containing the reduced coenzyme Q10. One or more e...
|
|
WO/2023/176875A1 |
The present description discloses a means for suppressing a decrease, through oxidation, of the reduced coenzyme Q10 when a solid composition containing the reduced coenzyme Q10 is preserved. One or more embodiments of the present inve...
|
|
WO/2023/176878A1 |
The present description discloses a means that is capable of suppressing a reduced coenzyme Q10 from decreasing due to oxidation when a solid composition containing the reduced coenzyme Q10 is preserved. One or more embodiments of the ...
|
|
WO/2023/176783A1 |
The present invention provides a solid composition comprising nicotinic acid amide, ascorbic acid, and tranexamic acid.
|
|
WO/2023/177351A1 |
The present disclosure concerns compounds and methods thereof for treating proliferative diseases, fibrosis, inflammatory diseases and/or immune inflammatory 5 diseases. The present disclosure also concerns methods of inhibiting NF-κB-i...
|
|
WO/2023/177249A1 |
The present invention pertains to a novel binary Histone deacetylase (HDAC) inhibitor, and a pharmaceutical composition containing same. More specifically, the compound according to the present invention exhibits more selective and super...
|
|
WO/2023/176920A1 |
Provided is a highly functional antisense oligonucleotide capable of inhibiting the biosynthesis of chondroitin sulfate. Provided is an antisense oligonucleotide capable of inhibiting the expression of a chondroitin sulfate N-acetylgal...
|
|
WO/2023/176952A1 |
The purpose of the present invention is to provide a means for controlling the proliferation of a bacterium in the intestine. Provided is a composition for controlling the proliferation of any one bacterium selected from the group consis...
|
|
WO/2023/176951A1 |
Provided is a means for controlling proliferation of Collinsella bacteria in the intestines. The present invention addresses the problem of providing a novel material that is capable of controlling proliferation of Collinsella bacteria. ...
|
|
WO/2023/176863A1 |
The present invention addresses the problem of providing an oligonucleotide having a novel chemical modification pattern that has RNA interference action and/or gene expression suppressing action. Provided is an oligonucleotide or a phar...
|
|
WO/2023/177191A1 |
The present invention relates to a composition for preventing or treating fibrotic diseases, the composition comprising a dimethylchalcone derivative as an active ingredient, and more specifically, to a composition for alleviating, preve...
|
|
WO/2023/176796A1 |
The problem to be solved by the present invention is to provide a novel scar formation inhibitor having, as an active ingredient, a compound that has not been conventionally known to have an effect for inhibiting scar formation. The pres...
|
|
WO/2023/173700A1 |
The present invention relates to a cationic material for tooth desensitization, a preparation method therefor, and an application thereof, for use in solving the technical problems in the prior art of long time consumption and limited tr...
|
|
WO/2023/174947A1 |
The present invention relates to compositions comprising an estetrol component for use in endothelial healing contributing to endothelial integrity. The invention further relates to associated uses and methods. The compositions of the pr...
|
|
WO/2023/177250A1 |
The present invention relates to a novel heterocyclic inhibitor for histone deacetylase (HDAC), a novel therapeutic agent for HDAC-associated diseases, and a pharmaceutical composition comprising same. More specifically, a compound accor...
|
|
WO/2023/177159A1 |
The present invention relates to a lyophilized formulation including a fusion protein of α-galactosidase A and a preparation method thereof, wherein the lyophilized formulation not only has storage stability by including a composition p...
|
|
WO/2023/176862A1 |
For example, the present invention provides a new siRNA that has a gene expression suppressing action and/or an RNA interference action with respect to mRNA encoding TfR2. The present invention pertains to: an oligonucleotide that has a ...
|
|
WO/2023/176950A1 |
Provided is a means for controlling the proliferation of any one bacterium selected from the group consisting of a bacterium belonging to the genus Faecalibacterium, a bacterium belonging to the genus Akkermansia, a bacterium belonging t...
|
|
WO/2023/171806A1 |
The present invention provides a novel therapeutic or prophylactic agent that can treat or prevent diseases associated with mitochondrial dysfunctions. The present invention provides a therapeutic or prophylactic agent for diseases assoc...
|
|
WO/2023/172148A1 |
This invention relates to the use of paracetamol, ibuprofen and xylometazoline (or a pharmaceutically acceptable salt thereof) in the production of a medication for use in treating cold and/or flu in a human, by administering or taking: ...
|
|
WO/2023/171736A1 |
The purpose of the present invention is to provide a medicine for promoting differentiation induction from oligodendrocyte progenitor cells to oligodendrocytes, and a medicine for promoting remyelination. The present invention is a medic...
|
|
WO/2023/170543A1 |
The present invention relates to fluorinated amphiphilic dendrimer structures (FJDs) capable of self-assembling into supramolecular systems of different size and shape. A further object is a supramolecular complex comprising at least one...
|
|
WO/2023/171714A1 |
[Problem] To provide a novel therapeutic agent, for bronchial asthma, that focuses on CD109. [Solution] This pharmaceutical composition contains, as an active component, a drug that improves bronchial hypersensitivity and/or eosinophilic...
|
|
WO/2023/171789A1 |
The present addresses the problem of providing a novel composition for treating myocarditis and/or a novel composition for preventing myocarditis. Provided is a composition for preventing or treating myocarditis, the composition compri...
|
|
WO/2023/171106A1 |
An agent for suppressing aggregation of TDP-43, the agent comprising at least one selected from the group consisting of cycloserine, terizidone, and salts thereof.
|
|
WO/2023/171719A1 |
The purpose of the present invention is to provide a breakthrough activated protein C that can cure protein C deficiency, a pharmaceutical composition containing the same, etc. The present invention provides a polypeptide, which contains...
|
|
WO/2023/167094A1 |
Disclosed are a 5'-modified nucleoside and a nucleotide using the same. The nucleoside of the present invention is a compound represented by formula (I) or a salt thereof. The nucleoside of the present invention has suitable duplex-formi...
|
|
WO/2023/167066A1 |
[Problem] To find a novel pharmaceutical or method for treating autoimmune diseases. [Solution] A combination of methotrexate and 5-ALAs.
|
|
WO/2023/167865A1 |
The present disclosure relates to compounds of Formula (T): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2023/167310A1 |
The present invention relates to a compound represented by formula (I) (in the formula, R1 is a substituted or unsubstituted C1-6 alkyl group, R2 is a hydrogen atom or an N,N-disubstituted carbamoyl group, Ar1 and Ar2 each independently ...
|
